Markus R. Lange

Markus R. Lange
Novartis · Research and Development

About

2
Publications
96
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
14
Citations
Citations since 2017
0 Research Items
12 Citations
2017201820192020202120222023012345
2017201820192020202120222023012345
2017201820192020202120222023012345
2017201820192020202120222023012345

Publications

Publications (2)
Article
Biologics such as monoclonal antibodies are increasingly and successfully used for the treatment of many chronic diseases. Unlike conventional small drug molecules, which are commonly given as tablets once daily, biologics are typically injected at much longer time intervals, that is, weeks or months. Hence, both the dose and the time interval have...
Article
Biologics, in particular monoclonal antibodies, are important therapies in serious diseases such as cancer, psoriasis, multiple sclerosis, or rheumatoid arthritis. While most conventional drugs are given daily, the effect of monoclonal antibodies often lasts for months, and hence, these biologics require less frequent dosing. A good understanding o...

Network

Cited By